Compare COOK & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | IVVD |
|---|---|---|
| Founded | 1985 | 2020 |
| Country | United States | United States |
| Employees | N/A | 122 |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.0M | 201.9M |
| IPO Year | 2021 | 2021 |
| Metric | COOK | IVVD |
|---|---|---|
| Price | $69.10 | $0.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $53.00 | $8.75 |
| AVG Volume (30 Days) | 54.5K | ★ 5.2M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $559,520,000.00 | $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | $3.07 | $41.42 |
| P/E Ratio | $61.87 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $0.48 | $0.49 |
| 52 Week High | $86.59 | $3.07 |
| Indicator | COOK | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 32.04 |
| Support Level | $60.87 | N/A |
| Resistance Level | $76.22 | $1.01 |
| Average True Range (ATR) | 5.74 | 0.07 |
| MACD | -1.29 | -0.01 |
| Stochastic Oscillator | 29.91 | 1.81 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.